Skip to content
AboutFrameworkInitiativesRM3PeopleEventsResources
Collaborate

Justified confidence in medical product safety and effectiveness.

Independent nonprofit neutral platform. MPSEI is a trademark of Medical Product Safety & Effectiveness Institute.

info@mpsei.org

Institute

  • About
  • Framework
  • People

Work

  • Initiatives
  • RM3
  • Events
  • Resources

Governance

  • RM3 antitrust statement
  • Collaborate
  • Contact

Medical Product Safety & Effectiveness Institute

PrivacyTermsAccessibility

Justified confidence in medical product safety and effectiveness.

MPSEI is a global, neutral platform for first-principles safety and effectiveness: advancing justified confidence and improving patient outcomes across the medical product ecosystem.

Explore the frameworkSee the RM3 model →
  1. 01First Principles
  2. 02Safety & Effectiveness
  3. 03Justified Confidence
  4. 04Decisions
  5. 05Patient Outcomes

The pathway begins with First Principles, moves through Safety & Effectiveness, Justified Confidence, and Decisions, and ends with Patient Outcomes.

The five-part MPSEI framework chain.

The argument

Observation to belief

To advance the science and practice of first-principles safety and effectiveness by aligning ecosystem stakeholders around shared first principles and fundamental objectives, and fostering education, collaboration, research, capability and maturity improvement, continuous learning, and recognition of demonstrated organizational proficiency across the global medical product ecosystem.

Safe and effective medical products do not result from compliance alone. They result from sound decisions and organizational proficiency grounded in fundamental truths, cause-and-effect relationships, evidence, engineering, risk management, continuous learning, and improvement.

Five foundational pillars

1

First-Principles Safety & Effectiveness

Establish the confidence framework by determining what must be true for a medical product to be safe and effective, and integrate that framework into product development and lifecycle management.

2

First-Principles Risk Management

Systematically apply inversion thinking within forward-thinking decision making. As we determine what is wanted or intended and how to achieve it, deliberately examine what is unwanted but could happen, how and why it could happen, and how it can be prevented or controlled. This first-principles approach integrates risk management into decision making throughout the medical product lifecycle.

3

First-Principles Decision Excellence & Organizational Maturity

Improve organizational proficiency and capability to consistently make sound safety and effectiveness decisions by applying first-principles thinking through effective leadership, governance, culture, evidence integration, cross-functional collaboration, and continuous learning, and provide the foundation for maturity assessment, benchmarking, continuous improvement, and recognition of demonstrated organizational proficiency.

4

Ecosystem Alignment & Collaboration

Align diverse healthcare ecosystem stakeholders around shared first principles and the fundamental objectives of medical product safety, effectiveness, and patient outcomes, while fostering collaboration, shared learning, and collective action across organizational, disciplinary, geographic, and lifecycle boundaries.

5

Continuous Assurance & Learning

Support lifecycle confidence through evidence, real-world experience, post-market learning, continuous monitoring, adaptation, and improvement.

Initiatives

Workstreams translate the confidence framework into education, research, and collaboration.

View all initiatives
1First-Principles Safety & Effectiveness Engineering for Medical Products→Establish the first-principles confidence framework and integrate it into product development and lifecycle management.
2First-Principles Risk Management for Medical Products→Systematically apply inversion thinking within forward-thinking decision making. As organizations determine what is wanted or intended and how to achieve it, they deliberately examine what is unwanted but could happen, how and why it could happen, and how it can be prevented or controlled, embedding effective risk management into decisions throughout the medical product lifecycle.
3First-Principles Decision Excellence & Organizational Maturity→Improve organizational proficiency and capability to consistently make sound safety and effectiveness decisions by applying first-principles thinking through effective leadership, governance, culture, evidence integration, cross-functional collaboration, and continuous learning. Through the RM3 Framework, this initiative will support organizational assessment, targeted improvement, benchmarking, and recognition of demonstrated maturity.
4First-Principles Safety & Effectiveness Engineering for Combination Products→Apply the first-principles safety and effectiveness confidence framework to the integrated development and lifecycle management of combination products, including the justified reuse and bridging of platforms, prior knowledge, and evidence.
5First-Principles Safety & Effectiveness Engineering for AI→Apply the first-principles safety and effectiveness confidence framework to AI-enabled medical products and AI-enabled development and manufacturing processes, with an emphasis on continuous assurance as technologies and use conditions evolve.
6First-Principles Pharmaceutical Development & Lifecycle→Apply first-principles thinking to pharmaceutical development and lifecycle management by integrating product and process understanding, quality, risk management, manufacturing, and continuous improvement to build justified confidence in product safety and effectiveness.
7First-Principles Safety & Effectiveness Engineering for Cell & Gene Therapies→Apply the first-principles safety and effectiveness confidence framework to cell and gene therapy development, manufacturing, clinical delivery, and lifecycle management by integrating product and process understanding, patient-specific considerations, analytical characterization, manufacturing science, risk management, clinical evidence, and long-term learning.

Risk Management Maturity Model

The Risk Management Maturity Model is a collaborative industry initiative that helps organizations evaluate and strengthen risk management capabilities in medical product development and lifecycle management.

Go to RM3

RM3 Founding Community

A cross-industry community advancing risk management practice

Experience represented across pharmaceutical, biotechnology, medical-device, combination-product, consulting, and related fields.

Selected organizations represented in the RM3 founding community are shown below.

70+

volunteer contributors

AbbVie
B Braun
BD
Dexcom
GessNet
Gilead
GSK
Lilly
Medtronic
Merck
Olympus
Pfizer
Roche
West Pharma

Individuals participate; organization names indicate where members work, not corporate endorsement.

Updates

View RM3 updates
June 5, 2026

RM3 Manual V1.0 draft ready for community review

At the June 5, 2026 IMSC panel, the RM3 working group reported that the RM3 Manual V1.0 draft was ready for broad community review and comment.

June 5, 2026

IMSC26 RM3 Panel

An RM3 panel at the International MedTech Safety Conference introduced the initiative's goals, structure, progress, guiding principles, maturity domains, and initial assessment concepts.

February 28, 2026

RAPS Safety Engineering Workshop

The first-principles approach to safety and effectiveness engineering was presented at the RAPS Safety Engineering Workshop on February 28, 2026.

Together, we will improve patient outcomes.

By aligning stakeholders around first principles and building justified confidence in medical product safety and effectiveness.

Collaborate

A wireframe clipboard shows outcome record lines and a physiological signal; a single improvement trajectory rises from the record to one validated outcome node.